Targeting unique metabolic properties of breast tumor initiating cells

Stem Cells

Volumn 32, Issue 7, 2014, Pages 1734-1745

  Feng, Weiguo ^a   Gentles, Andrew ^b,c   Nair, Ramesh V ^b,c   Huang, Min ^a   Lin, Yuan ^a   Lee, Cleo Y ^a   Cai, Shang ^a   Scheeren, Ferenc A ^a   Kuo, Angera H ^a   Diehn, Maximilian ^a,b  

^a Cancer Institute Institute for Stem Cell Biology and Regenerative Medicine   (United Kingdom)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast tumor initiating cells or cancer stem cells; Dichloroacetic acid; Glycolysis Oxidative phosphorylation; Metabolic reprogramming; Warburg effect

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; PYRUVATE DEHYDROGENASE; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; DICHLOROACETIC ACID; PYRUVATE DEHYDROGENASE COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CELL ISOLATION; CELL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; NONTUMORIGENIC CANCER CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR INITIATING CELL; ANIMAL; CANCER TRANSPLANTATION; CELL SEPARATION; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; METABOLISM; MITOCHONDRIAL GENE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SEQUENCE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SEPARATION; DICHLOROACETIC ACID; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, MITOCHONDRIAL; GLYCOLYSIS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PYRUVATE DEHYDROGENASE COMPLEX; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME;

EID: 84902587472     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1662     Document Type: Article

References (66)

1. Warburg O, Posener, K,., Negelein, E,. Über den stoffwechsel der tumoren. Biochemische. Zeitschrift 1924: 25.
2. Warburg O,. Note on the metabolism of tumours. Biochemische Zeitschrift 1930; 228: 257-258.
3. Hsu PP, Sabatini DM,. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
5. Cho RW, Wang X, Diehn M, et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008; 26: 364-371.
6. Ailles L, Prince M,. Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol Biol 2009; 568: 175-193.
7. Chu P, Clanton DJ, Snipas TS, et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009; 124: 1312-1321.
8. Cocciadiferro L, Miceli V, Kang KS, et al. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann N Y Acad Sci 2009; 1155: 257-262.
9. Cui F, Wang J, Chen D, et al. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep 2011; 25: 701-708.
10. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
11. Palapattu GS, Wu C, Silvers CR, et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009; 69: 787-798.
12. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
13. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
14. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674-4682.
15. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
16. Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488: 522-526.
17. Driessens G, Beck B, Caauwe A, et al. Defining the mode of tumour growth by clonal analysis. Nature 2012; 488: 527-530.
18. Schepers AG, Snippert HJ, Stange DE, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-735.
19. Chen ZG,. The cancer stem cell concept in progression of head and neck cancer. J Oncol 2009; 2009: 894064.
20. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-314.
21. Krzeslak A, Wojcik-Krowiranda K, Forma E, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012; 18: 721-728.
22. Paudyal B, Oriuchi N, Paudyal P, et al. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 2008; 99: 260-266.
23. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
24. Haraguchi N, Ishii H, Mimori K, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-3339.
25. Phillips TM, McBride WH, Pajonk F,. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777-1785.
26. Izyumov DS, Domnina LV, Nepryakhina OK, et al. Mitochondria as source of reactive oxygen species under oxidative stress. Study with novel mitochondria-targeted antioxidants-The «Skulachev-ion» derivatives. Biochemistry (Mosc) 2010; 75: 123-129.
27. Simsek T, Kocabas F, Zheng J, et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010; 7: 380-390.
28. Takubo K, Nagamatsu G, Kobayashi CI, et al. Regulation of glycolysis by pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 2013; 12: 49-61.
29. Varum S, Rodrigues AS, Moura MB, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One 2011; 6: e20914.
30. Kondoh H, Lleonart ME, Nakashima Y, et al. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 2007; 9: 293-299.
31. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
32. Newton MA, Quintana FA, Den Boon JA, et al. Random-set methods identify distinct aspects of the enrichment signal in gene-set analysis. Ann Appl Stat 2007; 1: 85-106.
33. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
34. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
35. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
36. Kim M, Cooper DD, Hayes SF, et al. Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux. Blood 1998; 91: 4106-4117.
37. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11: 37-51.
38. Stacpoole PW,. The pharmacology of dichloroacetate. Metabolism 1989; 38: 1124-1144.
39. Stacpoole PW, Lorenz AC, Thomas RG, et al. Dichloroacetate in the treatment of lactic acidosis. Ann Intern Med 1988; 108: 58-63.
40. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117: 1519-1531.
41. Michelakis ED, Webster L, Mackey JR,. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989-994.
42. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2010;2:31ra34.
43. Ma J, Lanza DG, Guest I, et al. Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. Tumour Biol 2012; 33: 1983-1996.
44. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
45. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
46. Lee CY, Lin Y, Bratman S, et al. Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res 2014; 74: 341-352.
47. Randall TD, Lund FE, Howard MC, et al. Expression of murine CD38 defines a population of long-term reconstituting hematopoietic stem cells. Blood 1996; 87: 4057-4067.
48. Fillmore C, Kuperwasser C. Human breast cancer stem cell markers CD44 and CD24: Enriching for cells with functional properties in mice or in man? Breast Cancer Res 2007; 9: 303.
49. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
50. Cho YM, Kwon S, Pak YK, et al. Dynamic changes in mitochondrial biogenesis and antioxidant enzymes during the spontaneous differentiation of human embryonic stem cells. Biochem Biophys Res Commun 2006; 348: 1472-1478.
51. Vlashi E, Lagadec C, Vergnes L, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 2011; 108: 16062-16067.
52. Zhang WC, Shyh-Chang N, Yang H, et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012; 148: 259-272.
53. Morfouace M, Lalier L, Bahut M, et al. Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem 2012; 287: 33664-33674.
54. Menendez JA, Joven J, Cufi S, et al. The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle 2013; 12: 1166-1179.
55. Pecqueur C, Oliver L, Oizel K, et al. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol 2013; 2013: 805975.
56. Mao P, Joshi K, Li J, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013; 110: 8644-8649.
57. Lemons JM, Feng XJ, Bennett BD, et al. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol 2010; 8: e1000514.
58. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
59. Nitta E, Yamashita M, Hosokawa K, et al. Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism. Blood 2011; 117: 4169-4180.
60. Tothova Z, Kollipara R, Huntly BJ, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128: 325-339.
61. Kondoh H, Lleonart ME, Bernard D, et al. Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization. Histol Histopathol 2007; 22: 85-90.
62. Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012; 109: 2784-2789.
63. Curry SH, Lorenz A, Chu PI, et al. Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm Drug Dispos 1991; 12: 375-390.
64. Bowker-Kinley MM, Davis WI, Wu P, et al. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998; 329 (Pt 1): 191-196.
65. Cairns RA, Papandreou I, Sutphin PD, et al. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 2007; 104: 9445-9450.
66. Stockwin LH, Yu SX, Borgel S, et al. Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 2010; 127: 2510-2519.